Alzheimer's disease

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common form of dementia in aging adults. The diagnosis is still primarily made on the basis of history and physical and neurologic examinations. The incidence increases rapidly with age, so the number of affected individuals with AD is ballooning rapidly. Cholinesterase inhibitors are mildly effective in treating cognitive and global functioning, as well as behavior abnormalities in patients with mild-, moderate-, or severe-stage disease. The N-methyl-D-aspartate (NMDA) antagonist memantine is similarly mildly effective alone or in combination with cholinesterase inhibitors in moderate to severe stages of the disease. No therapy is proven to delay disease progression, but recent insights into the pathophysiology of AD have led to promising investigational therapies, including the development of both γ- and β-secretase inhibitors as well as active and passive immunization against the amyloid β-protein.

Original languageEnglish
Pages (from-to)39-68
Number of pages30
JournalContinuum (Minneapolis, Minn.)
Volume13
Issue number2
DOIs
StatePublished - Apr 2007

Fingerprint

Alzheimer Disease
Cholinesterase Inhibitors
Memantine
Amyloidogenic Proteins
Amyloid Precursor Protein Secretases
Investigational Therapies
Passive Immunization
Neurologic Examination
N-Methylaspartate
Physical Examination
Dementia
Disease Progression
Vaccination
History
Incidence
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)

Cite this

Alzheimer's disease. / Farlow, Martin.

In: Continuum (Minneapolis, Minn.), Vol. 13, No. 2, 04.2007, p. 39-68.

Research output: Contribution to journalArticle

Farlow, Martin. / Alzheimer's disease. In: Continuum (Minneapolis, Minn.). 2007 ; Vol. 13, No. 2. pp. 39-68.
@article{46d903bcf61349419a7b5001650fc402,
title = "Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is the most common form of dementia in aging adults. The diagnosis is still primarily made on the basis of history and physical and neurologic examinations. The incidence increases rapidly with age, so the number of affected individuals with AD is ballooning rapidly. Cholinesterase inhibitors are mildly effective in treating cognitive and global functioning, as well as behavior abnormalities in patients with mild-, moderate-, or severe-stage disease. The N-methyl-D-aspartate (NMDA) antagonist memantine is similarly mildly effective alone or in combination with cholinesterase inhibitors in moderate to severe stages of the disease. No therapy is proven to delay disease progression, but recent insights into the pathophysiology of AD have led to promising investigational therapies, including the development of both γ- and β-secretase inhibitors as well as active and passive immunization against the amyloid β-protein.",
author = "Martin Farlow",
year = "2007",
month = "4",
doi = "10.1212/01.CON.0000267235.69379.07",
language = "English",
volume = "13",
pages = "39--68",
journal = "CONTINUUM Lifelong Learning in Neurology",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Alzheimer's disease

AU - Farlow, Martin

PY - 2007/4

Y1 - 2007/4

N2 - Alzheimer's disease (AD) is the most common form of dementia in aging adults. The diagnosis is still primarily made on the basis of history and physical and neurologic examinations. The incidence increases rapidly with age, so the number of affected individuals with AD is ballooning rapidly. Cholinesterase inhibitors are mildly effective in treating cognitive and global functioning, as well as behavior abnormalities in patients with mild-, moderate-, or severe-stage disease. The N-methyl-D-aspartate (NMDA) antagonist memantine is similarly mildly effective alone or in combination with cholinesterase inhibitors in moderate to severe stages of the disease. No therapy is proven to delay disease progression, but recent insights into the pathophysiology of AD have led to promising investigational therapies, including the development of both γ- and β-secretase inhibitors as well as active and passive immunization against the amyloid β-protein.

AB - Alzheimer's disease (AD) is the most common form of dementia in aging adults. The diagnosis is still primarily made on the basis of history and physical and neurologic examinations. The incidence increases rapidly with age, so the number of affected individuals with AD is ballooning rapidly. Cholinesterase inhibitors are mildly effective in treating cognitive and global functioning, as well as behavior abnormalities in patients with mild-, moderate-, or severe-stage disease. The N-methyl-D-aspartate (NMDA) antagonist memantine is similarly mildly effective alone or in combination with cholinesterase inhibitors in moderate to severe stages of the disease. No therapy is proven to delay disease progression, but recent insights into the pathophysiology of AD have led to promising investigational therapies, including the development of both γ- and β-secretase inhibitors as well as active and passive immunization against the amyloid β-protein.

UR - http://www.scopus.com/inward/record.url?scp=34247264969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247264969&partnerID=8YFLogxK

U2 - 10.1212/01.CON.0000267235.69379.07

DO - 10.1212/01.CON.0000267235.69379.07

M3 - Article

AN - SCOPUS:34247264969

VL - 13

SP - 39

EP - 68

JO - CONTINUUM Lifelong Learning in Neurology

JF - CONTINUUM Lifelong Learning in Neurology

SN - 1080-2371

IS - 2

ER -